1:58 PM
 | 
Apr 25, 2017
 |  BC Extra  |  Company News

Biogen climbs as Spinraza sales top consensus

Biogen Inc. (NASDAQ:BIIB) gained $10.03 to $286.89 after it reported 1Q17 earnings that beat a consensus estimate, including stronger than expected sales of Spinraza nusinersen. The company reported $47.4 million in sales of the spinal muscular atrophy treatment, up from $5 million in 4Q16 and topping the $16 million consensus.

FDA approved Spinraza in December 2016 to treat all SMA types, but some payers have limited coverage to SMA type 1 and implemented access restrictions. On Tuesday, CEO Michel Vounatsos told a conference...

Read the full 405 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >